Sporadic versus Radiation-Associated Angiosarcoma: A Comparative Clinicopathologic and Molecular Analysis of 48 Cases

Table 1

Summary of clinical features in radiation-associated angiosarcoma (RAA) patients.

Case no.	Sex	Primary Dx	Age 1° Dx	Rx	RT dose (Gy)	Interval to RAA (mos)	RAA Tx	Status	Interval to death or last f/u (mos)
1	F	L breast CA	50	L/RT/Raloxifene	60	37	Gem, taxotere/M	DOD	6.1
2	F	L breast CA	57	L/RT	64.6	89	Adria, ifos/M (bil)	A-NED	41.3
3	F	L breast CA	70	L/RT	60	63	M/taxol	A-NED	33.2
4	F	R breast CA	50	L/RT	61	57	Adria, ifos/M	A-NED	102.0
5	F	R breast CA	74	L/RT/Tm	52	84	Vinb, actin-D/M	A-NED	52.2
6	F	R breast CA	53	L/C/RT/Tm	64.6	93	M (bil)/Adria, ifos	A-NED	23.5
7	F	L breast CA	51	L/C/RT	54	141	M/Adria, ifos/RT/Adria, ifos	A	2.8
8	F	SCC, R Cheek	68	WLE/RT	70.2	78	WLE/RT (palliative)	DOD	11.0
9	M	Seminoma	26	WLE/RT	Co × 6 wks	419	Ifos/WLE/RT (63 Gy)	DOD	39.2
10	M	Prostate CA	72	WLE/RT	72	120	WLE	D	10.2
11	F	Hodgkin’s lymphoma	16	C/total nodal RT	NA	387	Adria, ifos/amputation	DOD	15.1

CA: carcinoma, SCC: squamous cell carcinoma, L: lumpectomy, RT: radiation therapy, C: chemotherapy, Gem: gemcitabine, Adria: adriamycin, Ifos: ifosfamide, Tm: tamoxifen, M: mastectomy, WLE: wide local excision, D: dead, DOD: dead of disease, A: alive, A-NED: alive-no evidence of disease.